GILEAD SCIENCES, INC. cotiza a 147.10 USD y tiene una capitalización bursátil de $182.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in pati…
| Periodo | 2026-10 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-6.75 | $2.03 | $1.86 |
| Estimado | $2.16 | $-7.25 | $1.91 | $1.81 |
| Sorpresa | — | +6.9% | +6.3% | +2.8% |
| Métrica | GILD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 78.8% | 57.0% | +21.8% |
| Operating Margin | 34.0% | -38.6% | +72.7% |
| Net Margin | 28.9% | -33.6% | +62.5% |
| FCF Margin | 32.1% | -13.9% | +46.0% |
| ROE | 37.5% | -40.4% | +77.9% |
| ROA | 14.4% | -32.0% | +46.4% |
| Current Ratio | 1.55 | 2.84 | -1.29 |
| Debt / Equity | 1.10 | 0.28 | +0.82 |